Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00437281 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

A Phase 1 study of Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 1
Development phase
65
Enrollment target
18
Study locations

NCT00437281 is a Phase 1 study of Epilepsies, Partial that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 65 participants, above the 56-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target (16% higher). The trial reports 18 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00437281, a Phase 1 study of Epilepsies, Partial, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 1
Development phase
65 participants
Enrollment target
18
Study locations

Study Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current medications.

Conditions Studied

Epilepsies, Partial

Interventions

  • DRUG Placebo
  • DRUG Pregabalin

Study Locations (18)

Florida

  • Pfizer Investigational Site - Gulf Breeze
  • Pfizer Investigational Site - Pensacola
  • Pfizer Investigational Site - Tampa
  • Pfizer Investigational Site - Tampa

Alabama

  • Pfizer Investigational Site - Mobile
  • Pfizer Investigational Site - Mobile

Arkansas

  • Pfizer Investigational Site - Jonesboro
  • Pfizer Investigational Site - Little Rock

Texas

  • Pfizer Investigational Site - Houston
  • Pfizer Investigational Site - San Antonio

Arizona

  • Pfizer Investigational Site - Phoenix

California

  • Pfizer Investigational Site - San Francisco

Missouri

  • Pfizer Investigational Site - Springfield

New York

  • Pfizer Investigational Site - Buffalo

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2007-04
Est. Completion 2012-11
Phase Phase 1

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00437281

The ClinicalTrials.gov registry entry for NCT00437281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 56-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target (16% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epilepsies, Partial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00437281 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Florida, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00437281 about?

NCT00437281 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures". The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current medications.

What is the current status of trial NCT00437281?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2007-04. Estimated completion is 2012-11.

What conditions does trial NCT00437281 study?

This clinical trial studies the following conditions: Epilepsies, Partial.

What interventions are being tested in trial NCT00437281?

The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).

Who is sponsoring clinical trial NCT00437281?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00437281 being conducted?

This trial has 18 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epilepsies, Partial

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Epilepsies, Partial

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.